One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast.
HS
PDE4-inhibitor
psoriasis
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
09
09
2019
accepted:
20
09
2019
pubmed:
3
10
2019
medline:
13
5
2020
entrez:
3
10
2019
Statut:
ppublish
Résumé
Hidradenitis suppurativa and psoriasis are chronic inflammatory skin disorders. The onset of these pathologies is due to the interaction between genetic, environmental, and immunological factors making them classifiable as immuno-mediated inflammatory diseases, deriving from immunological deregulation. The coexistence of hidradenitis suppurativa (HS) and psoriasis in the same patient is rare and choosing the right therapy to treat both the conditions can be challenging. Here, we report the case of a patient affected by multidrug-resistant psoriasis and HS who reached a complete healing with apremilast, suggesting its possible therapeutic role in patients showing both the diseases.
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Thalidomide
4Z8R6ORS6L
apremilast
UP7QBP99PN
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13089Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Augustin, M., Krüger, K., Radtke, M. A., Schwippl, I., & Reich, K. (2008). Disease severity, quality of life and health care in plaque-type psoriasis: A multicenter cross-sectional study in Germany. Dermatology (Basel, Switzerland), 216(4), 366-372. https://doi.org/10.1159/000119415
Edwards, C. J., Blanco, F. J., Crowley, J., Birbara, C. A., Jaworski, J., Aelion, J., … Bird, P. (2016). Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: A phase III, randomised, controlled trial (PALACE 3). Annals of the Rheumatic Diseases, 75(6), 1065-1073. https://doi.org/10.1136/annrheumdis-2015-207963
Giuseppe, P., Nicola, P., Valentina, C., Elena, C., Salvatrice, C., Rosario, G., & Rita, B. M. (2018). A case of moderate hidradenitis suppurativa and psoriasis treated with secukinumab. Annals of Dermatology, 30(4), 462-464. https://doi.org/10.5021/ad.2018.30.4.462
Houslay, M. D., Schafer, P., & Zhang, K. Y. J. (2005). Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discovery Today, 10(22), 1503-1519. https://doi.org/10.1016/S1359-6446(05)03622-6
Kerdel, F. R., Azevedo, F. A., Kerdel Don, C., Don, F. A., Fabbrocini, G., & Kerdel, F. A. (2019). Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study. Journal of Drugs in Dermatology, 18(2), 170-176.
Lanna, C., Mancini, M., Gaziano, R., Cannizzaro, M. V., Galluzzo, M., Talamonti, M., … Bianchi, L. (2019). Skin immunity and its dysregulation in psoriasis. Cell Cycle (Georgetown, Tex.), 18(20), 2581-2589. https://doi.org/10.1080/15384101.2019.1653099
Lim, S. Y. D., & Oon, H. H. (2019). Systematic review of immunomodulatory therapies for hidradenitis suppurativa. Biologics: Targets & Therapy, 13, 53-78. https://doi.org/10.2147/BTT.S199862
Patel, M., Cohen, J. M., Wright, N. A., Merola, J. F., Qureshi, A. A., & Vleugels, R. A. (2015). Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): Experience of a tertiary medical center. Journal of the American Academy of Dermatology, 73(4), 701-702. https://doi.org/10.1016/j.jaad.2015.06.050
Santos, J. V., Lisboa, C., Lanna, C., Costa-Pereira, A., & Freitas, A. (2016). Hospitalisations with hidradenitis suppurativa: An increasing problem that deserves closer attention. Dermatology (Basel, Switzerland), 232(5), 613-618. https://doi.org/10.1159/000448515
Sawyer, L. M., Cornic, L., Levin, L. Å., Gibbons, C., Møller, A. H., & Jemec, G. B. (2019). Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. Journal of the European Academy of Dermatology and Venereology, 33(2), 355-366. https://doi.org/10.1111/jdv.15277
van der Zee, H. H., de Ruiter, L., van den Broecke, D. G., Dik, W. A., Laman, J. D., & Prens, E. P. (2011). Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: A rationale for targeting TNF-α and IL-1β. The British Journal of Dermatology, 164(6), 1292-1298. https://doi.org/10.1111/j.1365-2133.2011.10254.x
Weber, P., Seyed Jafari, S. M., Yawalkar, N., & Hunger, R. E. (2017). Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients. Journal of the American Academy of Dermatology, 76(6), 1189-1191. https://doi.org/10.1016/j.jaad.2017.02.026